These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23360067)

  • 1. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.
    Zheng Z; Miller MS; Jennings IG; Thompson PE
    ACS Chem Biol; 2013 Apr; 8(4):679-83. PubMed ID: 23360067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
    Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
    J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
    Kim J; Hong S; Hong S
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6977-81. PubMed ID: 22030027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions.
    Gratacap MP; Guillermet-Guibert J; Martin V; Chicanne G; Tronchère H; Gaits-Iacovoni F; Payrastre B
    Adv Enzyme Regul; 2011; 51(1):106-16. PubMed ID: 21035500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
    Zheng Z; Pinson JA; Mountford SJ; Orive S; Schoenwaelder SM; Shackleford D; Powell A; Nelson EM; Hamilton JR; Jackson SP; Jennings IG; Thompson PE
    Eur J Med Chem; 2016 Oct; 122():339-351. PubMed ID: 27387421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ.
    Collier PN; Messersmith D; Le Tiran A; Bandarage UK; Boucher C; Come J; Cottrell KM; Damagnez V; Doran JD; Griffith JP; Khare-Pandit S; Krueger EB; Ledeboer MW; Ledford B; Liao Y; Mahajan S; Moody CS; Roday S; Wang T; Xu J; Aronov AM
    J Med Chem; 2015 Jul; 58(14):5684-8. PubMed ID: 26121481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.
    Miller MS; Mountford SJ; Pinson JA; Zheng Z; Künzli M; Patel V; Hogg SJ; Shortt J; Jennings IG; Thompson PE
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4790-4794. PubMed ID: 27561716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.
    Nacht M; Qiao L; Sheets MP; St Martin T; Labenski M; Mazdiyasni H; Karp R; Zhu Z; Chaturvedi P; Bhavsar D; Niu D; Westlin W; Petter RC; Medikonda AP; Singh J
    J Med Chem; 2013 Feb; 56(3):712-21. PubMed ID: 23360348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
    Sabbah DA; Vennerstrom JL; Zhong HA
    J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
    Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
    J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
    Staben ST; Ndubaku C; Blaquiere N; Belvin M; Bull RJ; Dudley D; Edgar K; Gray D; Heald R; Heffron TP; Jones GE; Jones M; Kolesnikov A; Lee L; Lesnick J; Lewis C; Murray J; McLean NJ; Nonomiya J; Olivero AG; Ord R; Pang J; Price S; Prior WW; Rouge L; Salphati L; Sampath D; Wallin J; Wang L; Wei B; Weismann C; Wu P
    Bioorg Med Chem Lett; 2013 May; 23(9):2606-13. PubMed ID: 23540645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.
    Frazzetto M; Suphioglu C; Zhu J; Schmidt-Kittler O; Jennings IG; Cranmer SL; Jackson SP; Kinzler KW; Vogelstein B; Thompson PE
    Biochem J; 2008 Sep; 414(3):383-90. PubMed ID: 18489260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition.
    Zheng Z; Amran SI; Thompson PE; Jennings IG
    Mol Pharmacol; 2011 Oct; 80(4):657-64. PubMed ID: 21778304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ.
    Pinson JA; Zheng Z; Miller MS; Chalmers DK; Jennings IG; Thompson PE
    ACS Med Chem Lett; 2013 Feb; 4(2):206-210. PubMed ID: 23795239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
    Ghigo A; Hirsch E
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.
    Flanagan JU; Shepherd PR
    Biochem Soc Trans; 2014 Feb; 42(1):120-4. PubMed ID: 24450638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.
    Han M; Zhang JZ
    J Chem Inf Model; 2010 Jan; 50(1):136-45. PubMed ID: 19928754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
    Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.